These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30318569)

  • 41. Prospective study of polydimethylsiloxane vs dextranomer/hyaluronic acid injection for treatment of vesicoureteral reflux.
    Moore K; Bolduc S
    J Urol; 2014 Dec; 192(6):1794-9. PubMed ID: 24928269
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is routine voiding cystourethrogram necessary following double hit for primary vesicoureteral reflux?
    Arlen AM; Scherz HC; Filimon E; Leong T; Kirsch AJ
    J Pediatr Urol; 2015 Feb; 11(1):40.e1-5. PubMed ID: 25725613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Postoperative ureteral obstruction after endoscopic treatment of vesicoureteral reflux with polyacrylate polyalcohol copolymer (Vantris®).
    Alizadeh F; Mazdak H; Khorrami MH; Khalighinejad P; Shoureshi P
    J Pediatr Urol; 2013 Aug; 9(4):488-92. PubMed ID: 23219423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized clinical trial comparing endoscopic treatment with dextranomer hyaluronic acid copolymer and Cohen's ureteral reimplantation for vesicoureteral reflux: long-term results.
    Garcia-Aparicio L; Rovira J; Blazquez-Gomez E; García-García L; Giménez-Llort A; Rodo J; Morales L
    J Pediatr Urol; 2013 Aug; 9(4):483-7. PubMed ID: 23602843
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute and delayed vesicoureteral obstruction after endoscopic treatment of primary vesicoureteral reflux with dextranomer/hyaluronic acid copolymer: why and how to manage.
    García-Aparicio L; Rodo J; Palazon P; Martín O; Blázquez-Gómez E; Manzanares A; García-Smith N; Bejarano M; de Haro I; Ribó JM
    J Pediatr Urol; 2013 Aug; 9(4):493-7. PubMed ID: 23507288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ureteral Obstruction After Endoscopic Treatment of Vesicoureteral Reflux: Does the Type of Injected Bulking Agent Matter?
    Friedmacher F; Puri P
    Curr Urol Rep; 2019 Jul; 20(9):49. PubMed ID: 31289951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of endoscopic treatment in the management of grade v primary vesicoureteral reflux.
    Menezes MN; Puri P
    Eur Urol; 2007 Nov; 52(5):1505-9. PubMed ID: 17517467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endoscopic treatment of primary vesicoureteral reflux in children with two different bulking agents, high success and low complication rates: Comparison of Dexell and Vantris.
    Doğan AB; Özkan KU; Güler AG; Karakaya AE
    Actas Urol Esp (Engl Ed); 2021 Oct; 45(8):545-551. PubMed ID: 34526255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of vesicoureteral reflux using endoscopic injection of nonanimal stabilized hyaluronic acid/dextranomer gel: initial experience in pediatric patients by a single surgeon.
    Yu RN; Roth DR
    Pediatrics; 2006 Aug; 118(2):698-703. PubMed ID: 16882825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subureteral injection of dextranomer/hyaluronic acid copolymer for persistent vesicoureteral reflux following ureteroneocystostomy.
    Jung C; DeMarco RT; Lowrance WT; Pope JC; Adams MC; Dietrich MS; Brock JW
    J Urol; 2007 Jan; 177(1):312-5. PubMed ID: 17162075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of pediatric vesicoureteral reflux using endoscopic injection of hyaluronic acid/dextranomer gel: intermediate-term experience by a single surgeon.
    Hsieh MH; Madden-Fuentes RJ; Lindsay NE; Roth DR
    Urology; 2010 Jul; 76(1):199-203. PubMed ID: 20035980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Learning from the learning curve: factors associated with successful endoscopic correction of vesicoureteral reflux using dextranomer/hyaluronic acid copolymer.
    Dave S; Lorenzo AJ; Khoury AE; Braga LH; Skeldon SJ; Suoub M; Farhat W; Pippi Salle JL; Bägli DJ
    J Urol; 2008 Oct; 180(4 Suppl):1594-9; discussion 1599-600. PubMed ID: 18710756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single center experience with endoscopic subureteral dextranomer/hyaluronic acid injection as first line treatment in 1,551 children with intermediate and high grade vesicoureteral reflux.
    Puri P; Kutasy B; Colhoun E; Hunziker M
    J Urol; 2012 Oct; 188(4 Suppl):1485-9. PubMed ID: 22906657
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What are the predictive factors leading to ureteral obstruction following endoscopic correction of VUR in the pediatric population?
    Chertin B; Mele E; Kocherov S; Zilber S; Gerocarni Nappo S; Capozza N
    J Pediatr Urol; 2018 Dec; 14(6):538.e1-538.e7. PubMed ID: 29885870
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical efficacy and safety in children with vesicoureteral reflux of a single injection of two different bulking agents--polydimethylsiloxane (Macroplastique) or dextranomer/hyaluronic acid copolymer (Deflux): a short-term prospective comparative study.
    Kim SO; Shin BS; Hwang IS; Hwang EC; Oh KJ; Jung SI; Kang TW; Kwon D; Park K; Ryu SB
    Urol Int; 2011; 87(3):299-303. PubMed ID: 21934268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endoscopic correction of vesicoureteral reflux in children using polyacrylate-polyalcohol copolymer (Vantris): 5-years of prospective follow-up.
    Warchoł S; Krzemień G; Szmigielska A; Bombiński P; Toth K; Dudek-Warchoł T
    Cent European J Urol; 2017; 70(3):314-319. PubMed ID: 29104797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Our experience using various injectable materials for the endoscopic treatment of vesicoureteral reflux].
    Cabezalí Barbancho D; Gómez Fraile A; López Vázquez F; López Díaz M; Aransay Bramtot A
    Arch Esp Urol; 2008 Mar; 61(2):269-77. PubMed ID: 18491746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term results of endoscopic treatment of vesicoureteral reflux in children: comparison of different bulking agents.
    Stredele RJ; Dietz HG; Stehr M
    J Pediatr Urol; 2013 Feb; 9(1):71-6. PubMed ID: 22212178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cost-effectiveness of dextranomer/hyaluronic acid copolymer for the management of vesicoureteral reflux. 2. Reflux correction at the time of diagnosis as a substitute for traditional management.
    Benoit RM; Peele PB; Cannon GM; Docimo SG
    J Urol; 2006 Dec; 176(6 Pt 1):2649-53; discussion 2653. PubMed ID: 17085183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Endoscopic Correction of Reflux Utilizing Polyacrylate Polyalcohol Bulking Copolymer (Vantris) as a Tissue Augmenting Substance: Lessons Learned Over the 10 Years of Experience.
    Dothan D; Kocherov S; Jaber J; Chertin B
    J Laparoendosc Adv Surg Tech A; 2021 Sep; 31(9):1073-1078. PubMed ID: 34161157
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.